Last $19.57 USD
Change Today -0.06 / -0.31%
Volume 171.9K
VIVO On Other Exchanges
Symbol
Exchange
NASDAQ GS
Frankfurt
As of 8:10 PM 08/29/14 All times are local (Market data is delayed by at least 15 minutes).

meridian bioscience inc (VIVO) Snapshot

Open
$19.67
Previous Close
$19.63
Day High
$19.73
Day Low
$19.42
52 Week High
01/10/14 - $27.72
52 Week Low
05/7/14 - $19.14
Market Cap
813.5M
Average Volume 10 Days
281.9K
EPS TTM
$0.85
Shares Outstanding
41.6M
EX-Date
07/31/14
P/E TM
23.0x
Dividend
$0.80
Dividend Yield
4.04%
Current Stock Chart for MERIDIAN BIOSCIENCE INC (VIVO)

meridian bioscience inc (VIVO) Related Bloomberg News

View More Bloomberg News

meridian bioscience inc (VIVO) Related Businessweek News

No Related Businessweek News Found

meridian bioscience inc (VIVO) Details

Meridian Bioscience Inc., an integrated life science company, manufactures, develops, sells, and distributes diagnostic test kits. These are used primarily for respiratory, gastrointestinal, viral, and parasitic infectious diseases. It also makes and distributes bulk antigens, antibodies, and reagents used by researchers and other diagnostic manufacturers. In addition, it contract-manufactures proteins and other biologicals for biopharmaceutical and biotechnology companies researching new drugs and vaccines. Its products and technologies are marketed to hospitals, reference labs, research centers, veterinary testing centers, physician offices, diagnostics manufacturers, and biotech companies in about 60 countries. Meridian, founded in 1976, is based in Cincinnati.

550 Employees
Last Reported Date: 11/29/13
Founded in 1976

meridian bioscience inc (VIVO) Top Compensated Officers

Chief Executive Officer and Director
Total Annual Compensation: $901.4K
Founder and Executive Chairman
Total Annual Compensation: $901.4K
Chief Financial Officer, Principal Financial ...
Total Annual Compensation: $393.7K
Executive Vice President of Operations and In...
Total Annual Compensation: $408.9K
President of Meridian Bioscience Europe and M...
Total Annual Compensation: $529.6K
Compensation as of Fiscal Year 2013.

meridian bioscience inc (VIVO) Key Developments

Meridian Bioscience and the University of Tennessee Research Foundation Enter into License Agreement for Electrokinetic Sensor Technology

Meridian Bioscience, Inc. announced that it has entered into a technology and commercial license agreement with the University of Tennessee Research Foundation (UTRF) for the development of an innovative new technology that has the potential to result in a low cost, point-of-care detection platform capable of detecting proteins, small molecules, bacteria and viruses in minutes. The University of Tennessee technology is based on electrokinetic impedance sensing using microelectrode sensor chips. These chips are able to directly detect very minute levels of a specific analyte from complex biological samples. The device works by measuring the change in electrical properties of the chip without the use of labels or expensive optical instrumentation. In addition, detection occurs in a very specific area of the chip which lessens the amount of sample required and eliminates complex sample processing inherent to other diagnostic technologies, including PCR. The University of Tennessee scientific team has demonstrated the effectiveness of this sensor technology by detecting tuberculosis, a disease which is estimated to be responsible for the deaths of two million people annually worldwide. Meridian has validated these findings by detecting the human Influenza A virus directly from clinical samples in approximately two minutes.

Ellingwood Joins Meridian Bioscience, Inc.'s Board of Directors

Meridian Bioscience, Inc. announced that Ellingwood has joined Meridian's Board of Directors. At Cincinnati Children's Hospital Medical Center since 1997, Mr. Ellingwood previously served as Senior Vice President of Planning and Business Development, developing institutional strategy and leading organizational initiatives to pursue the institution's vision to be the leader in improving child health.

Meridian Bioscience, Inc. Reports Unaudited Earnings Results for the Third Quarter and Nine Months Ended June 30, 2014; Reaffirms Earnings Guidance for the Fiscal Year Ending September 30, 2014; Declares Cash Dividend for the Third Quarter Ended June 30, 2014, Payable on August 14, 2014

Meridian Bioscience, Inc. reported unaudited earnings results for the third quarter and nine months ended June 30, 2014. For the quarter, the company reported net sales of $47.21 million against $47.11 million reported last year. Operating income was at $13.13 million against $15.70 million reported last year. Earnings before income taxes was at $12.88 million against $15.55 million reported last year. Net earnings for the quarter were at $8.84 million or $0.21 per diluted share against $10.16 million or $0.24 per diluted share reported last year. For the nine month period, the company reported net sales of $142.14 million against $139.72 million reported last year. Operating income was at $40.42 million against $44.04 million reported last year. Earnings before income taxes was at $39.93 million against $44.31 million reported last year. Net earnings for the period were at $26.56 million or $0.63 per diluted share against $28.88 million or $0.69 per diluted share reported last year. The Board of Directors of the company declared the regular quarterly cash dividend of $0.20 per share for the third quarter ended June 30, 2014. The dividend is of record August 4, 2014 and payable August 14, 2014. This annual indicated dividend rate of $0.80 per share represents a 5% increase over the rate in fiscal 2013. For the fiscal year ending September 30, 2014, management expects net sales to be in the range of $190 million to $195 million and per share diluted earnings to be between $0.85 and $0.90. The per share estimates assume an increase in average diluted shares outstanding from approximately 41.9 million at fiscal 2013 year end to approximately 42.3 million at fiscal 2014 year end.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
VIVO:US $19.57 USD -0.06

VIVO Competitors

Market data is delayed at least 15 minutes.

Company Last Change
ERBA Diagnostics Inc $3.63 USD +0.02
Luminex Corp $18.85 USD +0.44
Nanosphere Inc $0.84 USD +0.0088
Neogen Corp $42.10 USD +0.35
OraSure Technologies Inc $8.33 USD +0.07
View Industry Companies
 

Industry Analysis

VIVO

Industry Average

Valuation VIVO Industry Range
Price/Earnings 23.1x
Price/Sales 4.3x
Price/Book 5.0x
Price/Cash Flow 22.8x
TEV/Sales 4.1x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact MERIDIAN BIOSCIENCE INC, please visit www.meridianbioscience.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.